Abstract
Only 1 in 5 patients started on buprenorphine treatment were retained for at least 180 days from January 2016 through October 2022, a recent study has found. During that same period, the monthly initiation rate at first increased, and then flattened (prior to the COVID‐19 epidemic). The study, “Trends in Buprenorphine Initiation and Retention in the United States, 2016‐2022,” published in JAMA on April 25, is based on the IQVIA Longitudinal Prescription Database, which covers more than 90% of all prescriptions to pharmacies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
